RPTP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RPTP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Raptor Pharmaceutical's total inventories for the quarter that ended in Jun. 2016 was $12.0 Mil. Raptor Pharmaceutical's average total inventories from the quarter that ended in Mar. 2016 to the quarter that ended in Jun. 2016 was $10.8 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Raptor Pharmaceutical's Net-Net Working Capital per share for the quarter that ended in Jun. 2016 was $-1.70.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Raptor Pharmaceutical's Days Inventory for the three months ended in Jun. 2016 was 199.42.
Inventory Turnover measures how fast the company turns over its inventory within a year. Raptor Pharmaceutical's Inventory Turnover for the quarter that ended in Jun. 2016 was 0.46.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Raptor Pharmaceutical's Inventory-to-Revenue for the quarter that ended in Jun. 2016 was 0.34.
The historical data trend for Raptor Pharmaceutical's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raptor Pharmaceutical Annual Data | |||||||||||||||||||||
Trend | Dec06 | Dec07 | Dec08 | Aug09 | Aug10 | Aug11 | Aug12 | Dec13 | Dec14 | Dec15 | |||||||||||
Total Inventories | Get a 7-Day Free Trial | - | - | 3.00 | 9.13 | 6.42 |
Raptor Pharmaceutical Quarterly Data | ||||||||||||||||||||
Aug11 | Nov11 | Feb12 | May12 | Aug12 | Nov12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | |
Total Inventories | Get a 7-Day Free Trial | 5.32 | 6.75 | 6.42 | 9.60 | 12.03 |
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Raptor Pharmaceutical (NAS:RPTP) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Raptor Pharmaceutical's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2016 is
Net-Net Working Capital Per Share (Q: Jun. 2016 ) | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (124.239 | + | 0.75 * 15.727 | + | 0.5 * 12.031 | - | 287.249 |
- | 0 | - | 0) | / | 85.531 | ||
= | -1.70 |
2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Raptor Pharmaceutical's Days Inventory for the three months ended in Jun. 2016 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Jun. 2016 ) | / | Cost of Goods Sold (Q: Jun. 2016 ) | * | Days in Period |
= | 10.8135 | / | 4.948 | * | 365 / 4 | |
= | 199.42 |
3. Inventory Turnover measures how fast the company turns over its inventory within a year.
Raptor Pharmaceutical's Inventory Turnover for the quarter that ended in Jun. 2016 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Jun. 2016 ) | / | Average Total Inventories (Q: Jun. 2016 ) |
= | 4.948 | / | 10.8135 | |
= | 0.46 |
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Raptor Pharmaceutical's Inventory to Revenue for the quarter that ended in Jun. 2016 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Jun. 2016 ) | / | Revenue (Q: Jun. 2016 ) |
= | 10.8135 | / | 32.045 | |
= | 0.34 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Thank you for viewing the detailed overview of Raptor Pharmaceutical's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Raymond Anderson | director | C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
Krishna R Polu | officer: Chief Medical Officer | C/O RAPTOR PHARMACEUTICAL CORP, 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949 |
Michael P Smith | officer: Chief Financial Officer | 887 GREAT NORTHERN WAY VANCOUVER A1 V5T 4T5 |
Suzanne Louise Bruhn | director | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746 |
Georges Gemayel | director | 550 HILLS DRIVE, BEDMINSTER NJ 07921 |
Llew Keltner | director | 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949 |
Christopher M Starr | director | C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
David Happel | officer: Chief Commercial Officer | 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949 |
Julie Smith | director, officer: President and CEO | C/O RAPTOR PHARMACEUTICAL CORP, 9 COMMERCIAL BLVD, SUITE 200, NOVATO CA 94949 |
Anthony Gregg Lapointe | director | PO BOX 83216, GAITHERSBURG MD 20883-3216 |
Erich Sager | director | 9 COMMERCIAL BLVD., SUITE 200, NOVATO CA 94949 |
Georgia Erbez | officer: Chief Financial Officer | 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
Vijay B Samant | director | 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121 |
Timothy P Walbert | director | 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062 |
Patrice Rioux | other: CMO, Raptor Therapeutics | C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.